Compugen to Engage in Notable Conversations at H.C. Wainwright Investment Conference

Compugen to Appear at H.C. Wainwright Annual Global Investment Conference

Compugen Ltd., a forward-thinking company specializing in cancer immunotherapy and advanced computational target discovery using AI, is set to participate in the renowned H.C. Wainwright 28th Annual Global Investment Conference. The event takes place in New York City from September 14 to 16, 2026.

The highlight of Compugen's participation will be a fireside chat scheduled for September 14, 2026, at 3:30 PM ET. Attendees can tune in via a live webcast available on Compugen's Investor Relations webpage at www.cgen.com. Additionally, a recording of this session will be accessible shortly after the live event, ensuring that interested stakeholders can catch up on the key discussions.

Individuals seeking to delve deeper into Compugen's innovations or arrange a one-on-one meeting during the conference are encouraged to reach out to their H.C. Wainwright representatives. This structured interaction embodies Compugen's commitment to transparency and proactive communication with its investors and partners.

About Compugen

Founded with the vision of transforming cancer treatment, Compugen is currently in the clinical-stage of developing groundbreaking immunotherapy solutions. Central to their mission is Unigen™, an AI-supported computational discovery platform that drives the identification of novel therapeutic targets. The company boasts a robust immuno-oncology pipeline featuring several promising candidates:

- COM701: This potential first-in-class anti-PVRIG antibody is currently being tested in a unique adaptive platform trial, specifically the MAIA-ovarian trial, aimed at maintenance therapy for patients with relapsed platinum-sensitive ovarian cancer.
- Rilvegostomig: A bispecific antibody targeting PD-1 and TIGIT, this innovative molecule is being developed in collaboration with AstraZeneca under a licensing agreement, involving multiple Phase 1, 2, and 3 clinical evaluations.
- GS-0321 (previously COM503): This high-affinity antibody, designed to inhibit the interaction between IL-18 binding protein and IL-18, is the focus of a Phase 1 trial being led by Compugen, following its strategic licensing agreement with Gilead.

Moreover, Compugen maintains a dedicated pipeline focusing on early-stage immuno-oncology research that aims to tackle various mechanisms enhancing the body’s immune response against cancer. The company’s shares are publicly traded on both NASDAQ and the Tel Aviv Stock Exchange, under the ticker symbol CGEN, reflecting its strong presence in the biotechnology sector.

For any inquiries regarding investor relations or media coverage, interested parties can connect with Lindsey Trickett, who serves as the Head of Investor Relations and Corporate Communications. She can be reached via email at [email protected] or by phone at +1 (628) 241-0071. As Compugen continues to innovate within the cancer treatment landscape, their participation in events like the H.C. Wainwright conference highlights their ongoing commitment to both scientific excellence and investor engagement.